Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
AbCellera Biologics Inc. (ABCL)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 |
| | 10-Q | 10-K | 8-K | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Gross profit | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Sales and marketing | 38.2% | 12.5% | 3.0% | 6.8% | 0.7% | 1.3% | 22.1% | 4.7% |
| Research and development | 362.7% | 500.7% | | 58.1% | 8.3% | 12.4% | 316.8% | 54.4% |
| General and administrative | 154.3% | 60.4% | 13.6% | 31.4% | 4.5% | 9.3% | 204.6% | 40.5% |
| EBITDA | -481.2% | -111.4% | 42.3% | -7.6% | 72.3% | 71.8% | -443.6% | -3.8% |
| Depreciation | 29.8% | -23.7% | 5.1% | 5.0% | 0.4% | 11.3% | 21.1% | 12.7% |
| EBITA | -511.0% | -87.7% | 37.2% | -12.6% | 71.9% | 60.4% | -464.7% | -16.5% |
| Amortization of intangibles | | 87.7% | | 5.7% | 0.8% | 1.9% | 45.4% | 8.9% |
| EBIT | -511.0% | -175.3% | 37.2% | -18.3% | 71.1% | 58.5% | -510.1% | -25.4% |
| Pre-tax income | -377.9% | -145.8% | 46.0% | -15.0% | 72.9% | 60.8% | -453.4% | -7.5% |
| Income taxes | -74.3% | -7.1% | 19.7% | -0.2% | 19.7% | 17.8% | -65.2% | 0.9% |
| Net income | -303.6% | -138.7% | 26.3% | -14.8% | 53.2% | 43.0% | -388.2% | -8.4% |
|